Referencias►
1.
Schulz V, Hansel R, Tyler VE.
Rational Phytotherapy: A Physicians' Guide to Herbal Medicine.
3rd ed. Berlin: Springer-Verlag; 1998:230.
2.
Schulz V, Hansel R, Tyler VE.
Rational Phytotherapy: A Physicians' Guide to Herbal Medicine.
3rd ed. Berlin: Springer-Verlag; 1998:231.
3.
Buck AC, Cox R, Rees RWM, et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton: A double-blind, placebo-controlled study.
Br J Urol. 1990;66:398 - 404.
4.
Becker H, Ebeling L. Conservative therapy of benign prostate hyperplasia (BPH) with CerniltonN. Results of a placebo-controlled double-blind study [translated from German].
Urologe
[B]. 1988;28:301 - 306.
5.
Rugendorff EW, Weidner W, Ebeling L, et al. Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia.
Br J Urol. 1993;71:433 - 438.
6.
Buck AC, Rees RWM, Ebeling L. Treatment of chronic prostatitis and prostatodynia with pollen extract .
Br J Urol. 1989;64:496 - 499.
7.
Suzuki T, Kurokawa K, Mashimo T, et al. Clinical effect of Cernilton in chronic prostatitis [in Japanese; English abstract].
Hinyokika Kiyo. 1992;38:489 - 494.
8.
Habib FK, Ross M, Buck AC, et al. In vitro evaluation of the pollen extract, cernitin T-60, in the regulation of prostate cell growth.
Br J Urol.
1990;66:393 - 397.
9.
Roberts KP, Iyer RA, Prasad G, et al. Cyclic hydroxamic acid inhibitors of prostate cancer cell growth: selectivity and structure activity relationships.
Prostate. 1998;34:92 - 99.
10.
Zhang X, Habib FK, Ross M, et al. Isolation and characterization of a cyclic hydroxamic acid from a pollen extract, which inhibits cancerous cell growth in vitro.
J Med Chem. 1995;38:735 - 738.
11.
Wojcicki J, Samochowiec L, Bartlomowicz B, et al. Effect of pollen extract on the development of experimental atherosclerosis in rabbits.
Atherosclerosis. 1986;62:39 - 45.
12.
Juzwiak S. Experimental evaluation of the effect of pollen extract on the course of paracetamol poisoning [in Polish; English abstract].
Ann Acad Med Stetin. 1993;39:57 - 69.
13.
Becker H, Ebeling L. Conservative therapy of benign prostate hyperplasia (BPH) with CerniltonN. Results of a placebo-controlled double-blind study [translated from German].
Urologe
[B]. 1988;28:301 - 306.
14.
Buck AC, Cox R, Rees RWM, et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton: A double-blind, placebo-controlled study.
Br J Urol.
1990;66:398 - 404.
15.
Maekawa M, Kishimoto T, Yasumoto R, et al. Clinical evaluation of Cernilton on benign prostatic hypertrophy - a multiple center double-blind study with Paraprost [in Japanese; English abstract].
Hinyokika Kiyo. 1990;36:495 - 516.
16.
Dutkiewicz S. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia.
Int Urol Nephrol. 1996;28:49 - 53.
17.
Dutkiewicz S. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia.
Int Urol Nephrol. 1996;28:49 - 53.
18.
Maekawa M, Kishimoto T, Yasumoto R, et al. Clinical evaluation of Cernilton on benign prostatic hypertrophy - a multiple center double-blind study with Paraprost [in Japanese; English abstract].
Hinyokika Kiyo. 1990;36:495 - 516.
19.
Loschen G, Ebeling L. Inhibition of the arachidonate metabolism by an extract of rye pollen [in German; English abstract].
Arzneimittelforschung. 1991;41:162 - 167.
20. Schulz V, Hansel R, Tyler VE. Rational Phytotherapy: A Physicians' Guide to Herbal Medicine. 3rd ed. Berlin: Springer-Verlag; 1998:230 - 231.
21.
Buck AC, Cox R, Rees RWM, et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton: A double-blind, placebo-controlled study.
Br J Urol. 1990;66:398 - 404.
22.
Winther K, Hedman C. Assessment of the effects of the herbal remedy Femal on the symptoms of premenstrual syndrome: a randomized, double-blind, placebo-controlled study.
Curr Ther Res Clin Exp. 2002;63:344 - 353.
